Convection-Enhanced Delivery in the Treatment of Epilepsy

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Convection-enhanced delivery (CED) is a novel drug-delivery technique that uses positive hydrostatic pressure to deliver a fluid containing a therapeutic substance by bulk flow directly into the interstitial space within a localized region of the brain parenchyma. CED circumvents the blood-brain barrier and provides a wider, more homogenous distribution than bolus deposition (focal injection) or other diffusion-based delivery approaches. A potential use of CED is for the local delivery of antiseizure agents, which would provide an epilepsy treatment approach that avoids the systemic toxicities of orally administered antiepileptic drugs and bystander effects on nonepileptic brain regions. Recent studies have demonstrated that brief CED infusions of nondiffusible peptides that inhibit the release of excitatory neurotransmitters, including ω-conotoxins and botulinum neurotoxins, can produce long-lasting (weeks to months) seizure protection in the rat amygdala-kindling model. Seizure protection is obtainable without detectable neurological or behavioral side effects. Although conventional diffusible antiepileptic drugs do confer seizure protection when administered locally by CED, the effect is transitory. CED is a potential approach for seizure protection that could represent an alternative to resective surgery in the treatment of focal epilepsies that are resistant to orally-administered antiepileptic drugs. The prolonged duration of action of nondiffusible toxins would allow seizure protection to be maintained chronically with infrequent reinfusions.

Original languageEnglish (US)
Pages (from-to)344-351
Number of pages8
JournalNeurotherapeutics
Volume6
Issue number2
DOIs
StatePublished - Apr 2009

Fingerprint

Convection
Epilepsy
Seizures
Anticonvulsants
Therapeutics
Conotoxins
Bystander Effect
Hydrostatic Pressure
Partial Epilepsy
Neurotoxins
Brain
Amygdala
Blood-Brain Barrier
Neurotransmitter Agents
Peptides
Injections
Pharmaceutical Preparations

Keywords

  • ω-conotoxin
  • antiepileptic drug
  • botulinum neurotoxin
  • Convection-enhanced delivery
  • drug delivery
  • epilepsy
  • kindling
  • seizure

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Pharmacology

Cite this

Convection-Enhanced Delivery in the Treatment of Epilepsy. / Rogawski, Michael A.

In: Neurotherapeutics, Vol. 6, No. 2, 04.2009, p. 344-351.

Research output: Contribution to journalArticle

@article{fb6abc0b391648c7ab8acd07d63ff52f,
title = "Convection-Enhanced Delivery in the Treatment of Epilepsy",
abstract = "Convection-enhanced delivery (CED) is a novel drug-delivery technique that uses positive hydrostatic pressure to deliver a fluid containing a therapeutic substance by bulk flow directly into the interstitial space within a localized region of the brain parenchyma. CED circumvents the blood-brain barrier and provides a wider, more homogenous distribution than bolus deposition (focal injection) or other diffusion-based delivery approaches. A potential use of CED is for the local delivery of antiseizure agents, which would provide an epilepsy treatment approach that avoids the systemic toxicities of orally administered antiepileptic drugs and bystander effects on nonepileptic brain regions. Recent studies have demonstrated that brief CED infusions of nondiffusible peptides that inhibit the release of excitatory neurotransmitters, including ω-conotoxins and botulinum neurotoxins, can produce long-lasting (weeks to months) seizure protection in the rat amygdala-kindling model. Seizure protection is obtainable without detectable neurological or behavioral side effects. Although conventional diffusible antiepileptic drugs do confer seizure protection when administered locally by CED, the effect is transitory. CED is a potential approach for seizure protection that could represent an alternative to resective surgery in the treatment of focal epilepsies that are resistant to orally-administered antiepileptic drugs. The prolonged duration of action of nondiffusible toxins would allow seizure protection to be maintained chronically with infrequent reinfusions.",
keywords = "ω-conotoxin, antiepileptic drug, botulinum neurotoxin, Convection-enhanced delivery, drug delivery, epilepsy, kindling, seizure",
author = "Rogawski, {Michael A}",
year = "2009",
month = "4",
doi = "10.1016/j.nurt.2009.01.017",
language = "English (US)",
volume = "6",
pages = "344--351",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Convection-Enhanced Delivery in the Treatment of Epilepsy

AU - Rogawski, Michael A

PY - 2009/4

Y1 - 2009/4

N2 - Convection-enhanced delivery (CED) is a novel drug-delivery technique that uses positive hydrostatic pressure to deliver a fluid containing a therapeutic substance by bulk flow directly into the interstitial space within a localized region of the brain parenchyma. CED circumvents the blood-brain barrier and provides a wider, more homogenous distribution than bolus deposition (focal injection) or other diffusion-based delivery approaches. A potential use of CED is for the local delivery of antiseizure agents, which would provide an epilepsy treatment approach that avoids the systemic toxicities of orally administered antiepileptic drugs and bystander effects on nonepileptic brain regions. Recent studies have demonstrated that brief CED infusions of nondiffusible peptides that inhibit the release of excitatory neurotransmitters, including ω-conotoxins and botulinum neurotoxins, can produce long-lasting (weeks to months) seizure protection in the rat amygdala-kindling model. Seizure protection is obtainable without detectable neurological or behavioral side effects. Although conventional diffusible antiepileptic drugs do confer seizure protection when administered locally by CED, the effect is transitory. CED is a potential approach for seizure protection that could represent an alternative to resective surgery in the treatment of focal epilepsies that are resistant to orally-administered antiepileptic drugs. The prolonged duration of action of nondiffusible toxins would allow seizure protection to be maintained chronically with infrequent reinfusions.

AB - Convection-enhanced delivery (CED) is a novel drug-delivery technique that uses positive hydrostatic pressure to deliver a fluid containing a therapeutic substance by bulk flow directly into the interstitial space within a localized region of the brain parenchyma. CED circumvents the blood-brain barrier and provides a wider, more homogenous distribution than bolus deposition (focal injection) or other diffusion-based delivery approaches. A potential use of CED is for the local delivery of antiseizure agents, which would provide an epilepsy treatment approach that avoids the systemic toxicities of orally administered antiepileptic drugs and bystander effects on nonepileptic brain regions. Recent studies have demonstrated that brief CED infusions of nondiffusible peptides that inhibit the release of excitatory neurotransmitters, including ω-conotoxins and botulinum neurotoxins, can produce long-lasting (weeks to months) seizure protection in the rat amygdala-kindling model. Seizure protection is obtainable without detectable neurological or behavioral side effects. Although conventional diffusible antiepileptic drugs do confer seizure protection when administered locally by CED, the effect is transitory. CED is a potential approach for seizure protection that could represent an alternative to resective surgery in the treatment of focal epilepsies that are resistant to orally-administered antiepileptic drugs. The prolonged duration of action of nondiffusible toxins would allow seizure protection to be maintained chronically with infrequent reinfusions.

KW - ω-conotoxin

KW - antiepileptic drug

KW - botulinum neurotoxin

KW - Convection-enhanced delivery

KW - drug delivery

KW - epilepsy

KW - kindling

KW - seizure

UR - http://www.scopus.com/inward/record.url?scp=62949187356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62949187356&partnerID=8YFLogxK

U2 - 10.1016/j.nurt.2009.01.017

DO - 10.1016/j.nurt.2009.01.017

M3 - Article

C2 - 19332329

AN - SCOPUS:62949187356

VL - 6

SP - 344

EP - 351

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 2

ER -